Managing the uncertainty of reform
What lies ahead for life sciences and health care?
2011 saw the passage into law of milestone healthcare legislation in the United States, and the beginnings of a sweeping overhaul of the entire U.S. healthcare system. The implications for stakeholders across the global healthcare continuum are potentially profound, but the process of reform is fraught with political risk. How can life science and healthcare companies manage for this uncertainty, and what lies ahead for the global industry after U.S. healthcare reform?
The Financial Times U.S. Healthcare and Life Sciences Conference, developed by the Financial Times (FT) in collaboration with Deloitte, will bring together an international line-up of industry experienced professionals/specialists, government decision-makers, and leading market commentators to review the shifting sands of the health care industry, and assess the bottom-line impacts and potential implications for business and commercial strategies.
Register for the 6 June 2012 event in New York City (#FTushc12 on Twitter) and explore this collection of global Deloitte thought leadership addressing conference topics and the ongoing change in the life sciences and healthcare industry.
|U.S. health reform
Health reform’s indirect impacts related to the changing nature of their relationships to other stakeholders, could demonstrate an even greater catalyst for transformation.
|Managing the uncertainty of reform: What lies ahead for life sciences and health care?
Listen to the podcast, featuring DTTL and Deloitte U.S. life science and health care industry leaders discussing the global implications of U.S. healthcare reform, personalized medicine, Comparative Effectiveness Research (CER), and more.
|The follow on biologics market: Enter at your own risk
Follow-on biologics (FOBs), also known as biosimilars, have gained tremendous attention in recent years. While the exact nature of the pathway has not been revealed, there is a growing consensus among experienced industry observers that the market will look very different than that of current small molecule generics.
|2011 Survey of health care consumers: Global and country reports
Deloitte survey of over 15,000 consumers in 12 countries offers a snapshot of how consumers view the performance of their respective health care systems as well as opportunities for improving the value proposition in each.
|Social networks in life sciences
Online social networks are everywhere and healthcare is no exception. They can now form faster and reach further than ever before, potentially transforming how doctors treat their patients and how patients and consumers manage their conditions. As patients, consumers, and physicians swap insights about medicine and treatment in online communities, the life sciences industry has a chance to get in on the conversation.
|Comparative Effectiveness Research in the United States: Update and implications
Learn more about Comparative Effectiveness Research (CER), which has been proposed as a way to align diagnostics and treatments with evidence and to understand the real-world, incremental value of health technologies in differing patient populations.
|Where is the ROI for targeted therapies?
Personalized medicine is the application of new methods of genetic analysis to diagnose, treat, and manage disease – or predisposition of disease – on an individual basis. It has the power to transform health care within the foreseeable future from a population-based model to a subpopulation and individual model and is already having a disruptive impact on the U.S. health care system.
|The pharmaceutical innovation dilemma
Is pharmaceutical R&D earning an ROI? Global collection features Deloitte thought leadership from around the world, and highlights Deloitte's role as lead sponsor of the Financial Times Global Pharma & Biotech Conference 2011 in London.